Saturday 17 October 2026 Export TRDA’s income statement to Excel — free account

Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024. In the quarter to June 2026, revenue fell 54.0%, EPS grew 2.88% and free cash flow fell 9.10%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.36 0.42 −8.79%

Follow TRDA

Alert me

Market cap: $186.1M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 3/9
Altman Z: 2.15
Beneish M: −6.07
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio Full definition →	+8 more quarters Free account	0.00	0.00	0.00	0.00
P/S ratio Full definition →		3.91	16.73	92.01	66.31
P/FCF ratio Full definition →		0.00	0.00	0.00	0.00
P/Operating CF Full definition →		(8.49)	(13.21)	(12.66)	(9.57)
P/B ratio Full definition →		0.71	1.39	1.95	1.33
Price to Tangible BV Full definition →		0.71	1.39	1.95	1.33
EV/Sales Full definition →		(1.40)	5.07	47.60	18.73
EV/EBITDA Full definition →		0.70	0.00	0.00	0.00
EV/Operating CF Full definition →		0.68	(1.00)	(2.07)	(0.65)
EV/FCF Full definition →		0.67	(1.00)	(2.07)	(0.65)
Quick Ratio Full definition →		13.66	12.17	13.32	10.47
Current Ratio Full definition →		14.08	12.53	13.90	10.89
Net Debt/EBITDA Full definition →		7.02	7.06	6.06	5.00
Debt/Assets Full definition →		0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →		0.00	0.00	0.00	0.00
Asset Turnover Full definition →		0.13	0.06	0.01	0.01
Operating CF/Net income Full definition →		0.64	0.82	1.05	0.76
Capex/Depreciation Full definition →		0.35	0.82	(0.17)	(0.03)
Research and Development Expense of Revenue Full definition →		2,376.77%	2,614.09%	3,777.60%	3,938.64%
Selling, General and Administrative Expense of Revenue Full definition →		638.41%	735.18%	1,157.03%	1,168.37%
Intangible Assets out of Total Assets Full definition →		0.00	0.00	0.00	0.00
Share Based Compensation of Revenue Full definition →		316.98%	335.49%	542.17%	573.50%
Graham Net Nets Full definition →		1.11	0.55	0.38	0.54
Graham Number Full definition →		0.00	0.00	0.00	0.00
Earnings Yield Full definition →		(42.93%)	(33.66%)	(31.62%)	(53.80%)
Free Cash Flow Yield Full definition →		(53.97%)	(30.46%)	(24.93%)	(43.23%)
Revenue per Share Full definition →		0.04	0.03	0.02	0.02
Operating CF per Share Full definition →		(0.68)	(0.78)	(1.00)	(0.77)
Capex per Share Full definition →		0.00	0.01	0.00	0.00
Free Cash Flow per Share Full definition →		(0.68)	(0.77)	(1.00)	(0.77)
Cash per Share Full definition →		7.88	7.16	6.09	5.28
Shareholders Equity per Share Full definition →		8.22	7.40	6.47	5.53
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		8.22	7.40	6.47	5.53
Free Cash Flow Full definition →		(28.14)	(32.00)	(41.74)	(32.47)
Working Capital Full definition →		314.24	281.80	247.68	211.33
Capital Expenditures Full definition →		0.17	0.21	(0.04)	(0.01)
Net Current Asset Value Full definition →		266.08	235.01	202.21	167.24
EV/EBIT Full definition →		0.71	0.00	0.00	0.00
Capex to Sales Full definition →		(0.11)	(0.16)	0.05	0.01
Price to Operating Income Full definition →		0.00	0.00	0.00	0.00
Other line items
Average Receivables Full definition →		1.90	2.43	1.42	1.00
Average Payables Full definition →		2.23	3.27	2.56	2.80
Average Assets Full definition →		483.74	451.85	411.00	373.83
Average Common Equity Full definition →		381.58	367.41	344.06	306.46

Show all line items

Columns are period end dates

Stockrow Weekly